Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00698009 · ClinicalTrials.gov registry record · Phase 2
Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00698009: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00698009 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00698009, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Primary: Evaluate safety, feasibility, persistence, and anti-tumor effect of infused haploidentical donor-derived natural killer (NK) cells and low-dose interleukin-2 (IL-2). Secondary: * Quantification of cytokine levels; * Assessment of NK cell immunophenotype and function.
Primary Outcome
Neuroblastoma International Response Criteria: Complete Response (CR): No evidence of disease (primary and metastasis) clinically \& radiographic studies, (homovanillic acid (HVA)/vanillylmandelic acid (VMA) normal). Very Good Partial Response (VGPR): \>90% reduction in primary tumor, resolution all metastatic tumor except bone. No new bone lesions and improvement on scan of all pre-existing lesions; HVA/VMA decreased \>90%. Partial Response (PR): 50-90% reduction primary and all measurable meta
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Mesna
- DRUG Interleukin-2
- BIOLOGICAL Natural Killer Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Why NCT00698009 stopped before completion
NCT00698009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00698009 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00698009 about?
NCT00698009 is a clinical study titled "Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma". Primary: Evaluate safety, feasibility, persistence, and anti-tumor effect of infused haploidentical donor-derived natural killer (NK) cells and low-dose interleukin-2 (IL-2). Secondary: * Quantification of cytokine levels; * Assessment of NK cell immunophenotype and function.
What is the current status of trial NCT00698009?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2008-06. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00698009?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Mesna (DRUG), Interleukin-2 (DRUG), Natural Killer Cell Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT00698009?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00698009's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia